北交所策略专题报告：开源证券IVD千亿市场CAGR超15%，聚焦北交所、新三板基因科技产业链

Group 1 - The IVD market in China is rapidly growing, with a market size of 118.5 billion yuan in 2023, driven by increasing clinical diagnostic demand and technological advancements, achieving a CAGR of 15.58% from 2016 to 2023 [1][24][23] - The global traditional IVD market was valued at 97 billion USD in 2022 and is expected to reach 121.8 billion USD by 2026, supported by technological innovations and the demand for early diagnosis and screening [1][27][24] - The IVD industry is segmented into various diagnostic methods, including immunodiagnostics, biochemical diagnostics, molecular diagnostics, and POCT, with immunodiagnostics being the most widely used due to its high sensitivity and accuracy [1][18][24] Group 2 - The North Exchange has four listed companies related to the gene medical and IVD industry chain: Danna Biological, Norseland, Sanyuan Gene, and Kangle Health [1][32] - There are 11 companies in the New Third Board related to the gene technology industry chain, including Baiying Biological, Bell Biological, and Kanghua Co., among others [1][35] - The North Exchange's medical and biological sector experienced a weekly decline of 2.83%, the smallest among five major industries, with 17.39% of medical and biological stocks rising [2][39][44] Group 3 - The report highlights the importance of IVD in clinical decision-making, as it provides critical diagnostic information throughout the disease treatment process, from initial diagnosis to monitoring and prognosis [1][15] - The IVD industry is characterized by a supply-side innovation driven by the discovery of new biomarkers, advancements in diagnostic technologies, and a growing demand for early diagnosis and precision medicine [1][27][24] - The report notes that the domestic IVD market is expected to continue its rapid growth due to factors such as population aging, increased healthcare spending, and the rising demand for accurate and early clinical diagnostic information [1][23][24]